

Boston Therapeutics

Innovators in Complex Carbohydrate Chemistry™

Diabetes

**Teach-in Presentation
November 6, 2013**


OTCQB: BTHE
www.bostonti.com

This presentation contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including changes from anticipated levels of revenues, future national or regional economic and competitive conditions, difficulties in developing the Company's technology platforms, retaining and expanding the Company's customer base, fluctuations in consumer spending on the Company's products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this presentation.

Boston Therapeutics' goal is to be a leading developer of novel compounds based on complex carbohydrate chemistry for the treatment of diabetes.

- PAZ320 uniquely positioned to capture market share of \$35B* diabetes drug market: Phase 2a clinical trial completed; Enrolling Phase 2b
- IP portfolio places the Company ahead of the curve in carbohydrate drug development
- Team with extensive expertise in regulatory and clinical development, with multiple submissions and approvals to the FDA
- Raised \$5.8 million in 2013 to support product portfolio near-term clinical requirements
- Submitted request to FDA for Pre-IND meeting to conduct Phase 3 study

- Growing interest in carbohydrates in drug design
 - Plays fundamental role in normal cell functions
 - Participates in cell-cell interactions
- David Platt, Ph.D. is an expert and pioneer in the use of galactomannan in drug design
 - Holder of more than ten patents
- Co-editor of *Carbohydrate Drug Design*
 - Influential volume in the design of drugs using complex carbohydrates
- Founder & CEO of three publicly traded companies:
 - International Gene Group / SafeScience (Nasdaq:SAFS) : Cancer
 - Pro-Pharmaceuticals now Galectin Therapeutics (Nasdaq: GALT) - Liver /cancer
 - Boston Therapeutics (OTCQB: BTHE) - Diabetes



Team

David Platt ,Ph.D.
Chief Executive Officer
Chief Financial Officer
Chairman of the Board

Background

- 2001-2009: CEO/Chairman of Pro-Pharmaceuticals, now Galectin Therapeutics (NASDAQ: GALT)
- 1995-2000: CEO, Chairman and founder of SafeScience Inc., a Nasdaq-listed company
- 1992-1995: CEO, Chairman and founder of Int'l Gene Group, the predecessor to SafeScience, Inc.
- 1989-1991: Research fellow at the Michigan Foundation (now Barbara Ann Karmanos Institute)
- Research fellow at the Weizmann Institute of Science, Rehovot, Israel
- Ph.D. in Chemistry in 1988 from Hebrew University in Jerusalem
- Published peer-reviewed articles and holds many patents, primarily in the field of carbohydrate chemistry

Kenneth A. Tasse, Jr.
President , Director

- Co-founder and President of Boston Therapeutics, Inc. since November 2010
- CEO & President of Boston Therapeutics from 2009 until merger with Avanyx Therapeutics
- Former President of TKCI (consulting firm for commercial finance) from 2007 to 2009

Anthony Squeglia
VP, Strategic Planning

- Former CFO for Galectin Therapeutics, Inc. (Nasdaq: GALT) and its predecessor company Pro-Pharmaceuticals, Inc. (Amex: PRW) from 2007 to 2012
- VP Investor Relations for Pro-Pharmaceuticals from 2003 to 2007
- Senior management positions at AT&T, ITT, Unisys, Summa Four, Quentra Networks and Colonial Penn
- BBA from Wharton, MBA from Pepperdine

Ed Shea
VP, Business Development

- 25 years of bio-pharmaceutical experience in commercial development, marketing and sales.
- 15+ years with Glaxo SmithKline in business development, sales, marketing, training and various leadership positions. Therapeutic focus in immunology and infectious diseases.
- Regional Sales Manager with Salix Pharmaceuticals. Therapeutic focus in gastroenterology.
- Senior Director of Business Development with two startup biopharmaceutical companies, Critical Therapeutics, Inc. and ViroPharma, Inc. Therapeutic focus in immunology.
- Holds a B.S. and an M.B.A. in Business/Marketing from Salve Regina University in Newport, RI.

Team

Dr. Peter Sheehan, M.D.
Advisor, Medical Director

Hana Chen-Walden, M.D.
Chief Medical Director

Yael Bobruff, Ph. D
Clinical Trials Advisor

Shih-Chun David Liu, Ph.D.
Scientific Advisor

Background

- American Diabetes Association:
 - Current President, NYC Leadership Council
 - Current Chairman of Cardiometabolic Risk Initiative
 - Former national Board Member
- Internationally respected Endocrinologist and diabetes specialist
- Clinical interest in peripheral artery disease, diabetic neuropathy, wound healing


- Specialist in regulatory affairs in the pharmaceutical industry in U.S. and Europe
- 30 years of regulatory experience with the EMEA and in individual European countries
- Consultant since 2004 for European Clinical and Regulatory Consultancy
- M.D. from University of Tel Aviv, Israel

- Post-Doc at Harvard University Medical School, Department of Systems Biology
- Extensive experience in Research. Lab work, Experimental design, project management, scientific writing.
- PhD from Stanford University in Molecular biology and Genetics
- MSc from Stanford University in Environmental Engineering
- Graduated from Hebrew university with a bachelor degree in Biology with an added specialized program in microbiology

- Research contributed to the fundamental understanding of the red blood cell membrane architecture and identified surface receptor for malaria invasion
- Published over sixty research papers in prestigious journals
- Former research scientist in the Biomedical Research Department at Tufts Medical School
- Associate Professor of Medicine, Tufts University School of Medicine since 1992
- Ph.D. in biochemistry from Carnegie-Mellon University
- VP, founder at HDM Systems Corp., a green power electronic devices developer

Diabetes Trend: A Growing Epidemic

US Population with Diagnosed Diabetes




Diabetes Facts (US)

- 25.8 million people with diabetes (8.3% of U.S. population)
 - 460% increase since 1980
- 79 million people considered pre-diabetic
- 1 of 3 US adults will have diabetes by 2050 if current trends continue
- Leading cause of:
 - kidney failure
 - non-traumatic lower-limb amputations
 - new cases of blindness
- Major cause of heart disease and stroke
- \$245 Billion in Direct and Indirect Cost to US Economy

Source: CDC Division of Diabetes Translation. National Diabetes Surveillance System and 2011 CDC Diabetes Fact Sheet

Diabetes Growth Projections 2012-2030

**Diabetes worldwide drug market size \$35 billion
Expected to grow to \$58 billion by 2018**



Source: International Diabetes Federation Diabetes Atlas 5th Edition: 2012 Update

Product	Description	Indication	Preclinical	Phase I	Phase II	Phase III
PAZ320	Chewable tablet taken prior to meals to manage post-meal sugar spike	Type 2 Diabetes				
IPOXYN	Injectable anti-necrosis drug	Lower-limb ischemia in diabetic patients				

- PAZ320 works non-systemically in the gastrointestinal tract limiting side effects
- IPOXYN is an injectable anti-necrosis drug intended to treat hypoxia, which is the lack of oxygen to living cells

Diabetes Complications

Eyes
(retinopathy)

Kidney
(nephropathy)


Lower limbs
(peripheral vascular disease)

Brain and cerebral circulation
(cerebro-vascular disease)

Heart and coronary circulation
(coronary heart disease)

Peripheral nervous system
(neuropathy)

Diabetic foot
(ulceration and amputation)



*Diabetes Atlas, 3rd edition.
International Diabetes Federation*

- A growing body of evidence suggests that **reducing post-meal plasma glucose excursions** is as important, or perhaps more important for achieving HbA1c goals.
- The relationship between hyperglycemia and cardiovascular disease is complex with evidence suggesting that an acute increase of glycemia, **particularly after a meal**, may have a direct detrimental effect on cardiovascular disease.
- Targeting **both post-meal plasma glucose and fasting plasma glucose** is an important strategy for achieving optimal glycemic control

International Diabetes Federation

2011 Guideline for Management of Post-Meal Glucose in Diabetes



Are there any drugs available that reduce my blood sugar spike after meals by 40%, that are non-systemic and have no serious side effects ??

PAZ320





- Complex carbohydrate chemical structure
- Chewable drug taken before meals intended for improved glycemic control in Type 2 diabetes
- Novel, non-systemic approach to blood sugar management
- Strong safety profile
 - No serious adverse events (SAE)

PAZ 320

Non-Systemic

*Works in the
gastrointestinal tract*



Most Diabetes Drugs

Systemic

*Typical mechanisms
involve interaction
with liver, kidney,
pancreas and cells*



Carbohydrate-hydrolyzing Enzyme Inhibitor (CHEI)

Goal: Reduction of Postmeal Glucose Elevation

Without PAZ320

Enzymes break down complex carbohydrates into simple sugars


Enzymes



- *Fast Glucose Release from Carbohydrate Foods*
- *Unhealthy Glucose Spike*
- *Directed systemically*

OTCQB:BTHE

Consume
Carbohydrate
Foods



With PAZ320

PAZ320 Inhibits enzymes that release glucose from complex carbohydrates

Enzymes

PAZ320 (CHEI)



- *Less Glucose Released from Carbohydrate Foods*
- *Controlled Glucose Increase*
- *Directed solely on the intestinal tract*

Published in AACE journal Endocrine Practice
July-August 2013 edition

- **45% patient response: 40% reduction in postprandial glucose excursion**
- No serious adverse events
- Sense of fullness was observed
- Works regardless of duration of diabetes
- Works regardless of other medications
- No significant hypoglycemia
- Mild GI effects


Trial conducted at Dartmouth Medical Center

OTCQB:BTHE

Phase II Trial Results

Responder Summary Average Area Under the Curve

(p-value: ANOVA Friedman 0.012)




Trial Type	Status	Patient Population	Goals
Phase II Study Dartmouth-Hitchcock Medical Center, US	Completed Data published in <i>Endocrine Practice</i> Q3 2013	<ul style="list-style-type: none"> 21 people with Type 2 diabetes Currently using oral agents or insulin 	<ul style="list-style-type: none"> Efficacy and safety In combination with oral anti-diabetic medications and insulin
Phase 2b Lisieux, France	Initiating	<ul style="list-style-type: none"> 24 people with Type 2 diabetes currently using metformin 	<ul style="list-style-type: none"> Efficacy and safety
Phase 3 US, Europe, Hong Kong, Korea and China	Planned Collaboration with US diabetes clinic	<ul style="list-style-type: none"> 300 patients 	<ul style="list-style-type: none"> Evaluation of the effects of PAZ320 on glucose HbA1c , AUC in patients currently taking metformin
Mechanism of Action Validation University of Minnesota	Initiated		<ul style="list-style-type: none"> To study and validate PAZ320 mechanism of inhibition of carbohydrate hydrolyzing enzymes

- Carbohydrate-based intravenous solution that may potentially prevent necrosis, or cell death
- Treats ischemia, or lack of oxygen supply to living cells
- New chemical entity, not a biologic agent therefore strong regulatory position compared to biologic competitors
- Prevent amputation associated with lower limb ischemia or diabetic foot
- Contains oxygen rechargeable iron which picks up oxygen in the lungs
- 5,000 times smaller than red blood cell (RBC)
- Requires no blood type matching

Necrosis: localized death of living tissue.

Ischemia: deficient supply of blood to a body part, **leading to necrosis**



Facts and Figures

Global Addressable Market: \$30 billion*

Indications in which **necrosis** occurs:

- Stroke
- Heart Disease
- Trauma
- Anemia
- Stroke is a leading cause of death in the US
- Over 800,000 people die in the US each year from cardiovascular disease and strokes
- Kidney Failure
- Diabetic Foot
- Surgery

Competitive Advantage

- No current drug available to treat or prevent necrosis
- Ischemia currently treated by high pressure (hyperbaric) chamber
- All oxygen therapeutic drugs have failed in FDA trials
- IPOXYN is stable and does not scavenge Nitric Oxide
- Stable at room temperature

Source: Center for Disease Control and Prevention; *bcc Research

2013 Milestones Achieved

- ✓ PAZ320 Phase 2a clinical trial results show significant 40% reduction in the elevation of post-meal blood sugars; no serious adverse events; initiated Phase 2b
- ✓ Principal investigators published PAZ320 Phase 2a clinical trial results in *Endocrine Practice*, peer-reviewed journal
- ✓ Submit IND questions to FDA

Product	2013	2014	2015	2016
PAZ320	<ul style="list-style-type: none"> • Initiate Phase 2b trial in France 	<ul style="list-style-type: none"> • File IND • Initiate Phase 3 pivotal study 	<ul style="list-style-type: none"> • Finalize Phase 3 clinical study 	<ul style="list-style-type: none"> • New Drug Application (NDA)
IPOXYN	<ul style="list-style-type: none"> • 	<ul style="list-style-type: none"> • Initiate pre-clinical experiments • Short term toxicity studies • Pre-IND meeting with FDA 	<ul style="list-style-type: none"> • IND application 	<ul style="list-style-type: none"> • First in human study indication

- Ticker: OTCQB – BTHE
- Share Price*: \$1.30
- 52-Week Range: \$0.15 - \$1.65
- Market Capitalization*: \$48M
- Shares Outstanding: 37M
- Headquarters: Manchester, NH

* As of 11/04/13

Key Investment Highlights:

- PAZ320 uniquely positioned to capture market share of \$35B diabetes drug market; Phase 2 preliminary clinical trials completed
- IP portfolio places the Company ahead of the curve in carbohydrate technology development
- The necessary resources for success are in place; seasoned senior team, cash reserves, IP portfolio
- BTHE is significantly undervalued

Boston Therapeutics

Innovators in Complex Carbohydrate Chemistry™

**Teach-in Presentation
November 6, 2013**

**OTCQB: BTHE
www.bostonti.com**

Boston Therapeutics, Inc.

Anthony Squeglia, VP of Strategic Planning

Phone: 603-935-9799

Email: anthony.squeglia@bostonti.com